Verge Builds Out Big Pharma AI Partnerships With AstraZeneca Deal
Executive Summary
Deal Snapshot: Two years into a three-year partnership with Lilly, Verge announced another deal, with AstraZeneca’s Alexion, just months after acquiring bragging rights with early clinical data for an AI-discovered product candidate.
You may also be interested in...
Novo Nordisk Looks To Bring AI/ML To Cardiometabolic Disease In Valo Health Deal
Deal Snapshot: The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform.
Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
BenevolentAI Slashes Jobs And Drug Programs
The UK firm, which uses artificial intelligence to discover and develop drugs, is hoping to save £45m by halving its workforce and trimming its pipeline.